La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Fortrea Holdings a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Fortrea Holdings..

Fortrea Holdings (NASDAQ:FTRE) Azioni, Catena delle Opzioni

Fortrea Holdings

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

News

Pre-Market Outlook

Markets

Trading Ideas

BEKE

FTRE

MNDY

Scopri i cinque titoli chiave da seguire nel pre-market di oggi, 12 agosto 2024, con focus su risultati e previsioni.

Pre-market: 5 titoli da monitorare oggi, 12 agosto 2024

Fortrea Holdings Inc

WIIM

Tidewater shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 revenue below estimates.

Earnings

American Realty Investors Q3 EPS Sales $11.607M Down From $12.526M YoY

Pebblebrook Hotel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.52 by 13.46 percent. The company reported quarterly sales of $404.530 million which beat the analyst consensus estimate of $400.423 million by 1.03 percent. This is a 2.21 percent increase over sales of $395.799 million the same period last year.

Earnings Beats

Pebblebrook Hotel Q3 2024 FFO $0.59 Beats $0.52 Estimate, Sales $404.530M Beat $400.423M Estimate

Fathom Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTHM#NASDAQ">FTHM</a>) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.18) by 122.22 percent. The company reported quarterly sales of $83.733 million which missed the analyst consensus estimate of $91.804 million by 8.79 percent. This is a 10.47 percent decrease over sales of $93.524 million the same period last year.

Earnings Misses

FTHM

Fathom Holdings Q3 2024 GAAP EPS $(0.40) Misses $(0.18) Estimate, Sales $83.733M Miss $91.804M Estimate

IOVA

Iovance Biotherapeutics shares are trading lower. The company reported Q3 financial results.

BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.52 by 15.38 percent. The company reported quarterly sales of $165.909 million which beat the analyst consensus estimate of $163.098 million by 1.72 percent. This is a 10.09 percent increase over sales of $150.708 million the same period last year.

BlackLine Q3 2024 Adj. EPS $0.60 Beats $0.52 Estimate, Sales $165.909M Beat $163.098M Estimate

Lyell Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.20) by 15 percent. This is unchanged from the same period last year. The company reported $34.00 thousand in sales this quarter. This is a 36.00 percent increase over sales of $25.00 thousand the same period last year.

LYEL

Lyell Immunopharma Q3 EPS $(0.17) Beats $(0.20) Estimate, Sales $34.00K Up From $25.00K YoY

AMN Healthcare Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) sees Q4 sales of $685.000 million-705.000 million vs $667.95 million estimate.

Guidance

AMN Healthcare Services Sees Q4 Sales $685.000M-705.000M vs $667.95M Est

The One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $0.01 by 3100 percent. The company reported quarterly sales of $193.975 million which missed the analyst consensus estimate of $215.463 million by 9.97 percent. This is a 152.30 percent increase over sales of $76.884 million the same period last year.

STKS

The One Group Hospitality Q3 2024 Adj. EPS $(0.30) Misses $0.01 Estimate, Sales $193.975M Miss $215.463M Estimate

Saul Centers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFS#NYSE">BFS</a>) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.43 by 11.63 percent. The company reported quarterly sales of $67.30 million which beat the analyst consensus estimate of $65.78 million by 2.31 percent. This is a 5.54 percent increase over sales of $63.77 million the same period last year.

Saul Centers Q3 2024 GAAP EPS $0.48 Beats $0.43 Estimate, Sales $67.30M Beat $65.78M Estimate

BILL

BILL Holdings shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 guidance above estimates

LivePerson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 52.94 percent increase over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $74.244 million which beat the analyst consensus estimate of $71.127 million by 4.38 percent. This is a 26.73 percent decrease over sales of $101.332 million the same period last year.

LPSN

LivePerson Q3 2024 GAAP EPS $(0.32) Misses $(0.22) Estimate, Sales $74.244M Beat $71.127M Estimate

ADEA

Adeia Files Multiple Patent Infringement Lawsuits Against Disney, Hulu, And ESPN In U.S. And Europe; Legal Actions Initiated In Delaware And Across European Courts

NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.30) by 100 percent. This is a 95.42 percent increase over losses of $(13.11) per share from the same period last year. The company reported quarterly sales of $2.44 million which missed the analyst consensus estimate of $2.62 million by 6.94 percent. This is a 1.61 percent decrease over sales of $2.48 million the same period last year.

NovaBay Pharmaceuticals Q3 EPS $(0.60) Misses $(0.30) Estimate, Sales $2.44M Miss $2.62M Estimate

Universal Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UEIC#NASDAQ">UEIC</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.12 by 16.67 percent. The company reported quarterly sales of $102.073 million which missed the analyst consensus estimate of $102.718 million by 0.63 percent. This is a 4.69 percent decrease over sales of $107.095 million the same period last year.

UEIC

Universal Electronics Q3 2024 Adj. EPS $0.10 Misses $0.12 Estimate, Sales $102.073M Miss $102.718M Estimate

BNED

Barnes & Noble Education Sees Prelim Q2 First Day Program Revenue $235M

Metallus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTUS#NYSE">MTUS</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.02) by 350 percent. The company reported quarterly sales of $227.200 million which missed the analyst consensus estimate of $274.367 million by 17.19 percent. This is a 35.86 percent decrease over sales of $354.200 million the same period last year.

MTUS

Metallus Q3 2024 Adj. EPS $(0.09) Misses $(0.02) Estimate, Sales $227.200M Miss $274.367M Estimate

ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.01) by 300 percent.

LOGC

ContextLogic Q3 2024 GAAP EPS $(0.04) Misses $(0.01) Estimate

Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(0.98) by 3.06 percent. This is a 35.71 percent decrease over losses of $(0.70) per share from the same period last year.

PLRX

Pliant Therapeutics Q3 EPS $(0.95) Beats $(0.98) Estimate

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 33.33 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $36.325 million which beat the analyst consensus estimate of $35.609 million by 2.01 percent. This is a 7.39 percent decrease over sales of $39.222 million the same period last year.

ONTF

ON24 Q3 2024 Adj. EPS $0.02 Beats $0.00 Estimate, Sales $36.325M Beat $35.609M Estimate

Agilent Technologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Fortrea Holdings

Fortrea Holdings (FTRE) Opzioni

Fortrea Holdings (NASDAQ:FTRE) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO